ASX/AIM Announcement                                                                                  9 September 2025

Wellnex Life Limited (ASX/AIM:WNX)

Appointment of Non-Executive Chair

Wellnex Life Limited ("Wellnex" or the "Company") (ASX:WNX  AIM:WNX) is pleased to advise that the Board intends to appoint a new Non-Executive Chair.

Subject to this appointment, Mr. Andrew Vidler, who has served as Interim Non-Executive Chairman over the past five months, will step down from this role and continue to serve on the Board as an Independent Non-Executive Director. The Board acknowledges and thanks Mr Vidler for his contribution during this period.

The Board also welcomes the appointment of Ash Vesali as new Non-executive Chairman, further enhancing the skills and experience available to guide the Company through its next phase of growth. Mr Vesali's appointment is subject to the completion of customary due diligence by the Company's Nominated Advisor on AIM.

Mr Vesali brings over 20 years of global experience across high volume manufacturing and top-tier consulting, supporting ASX executives and boards on strategy, governance, performance improvement and business resiliency. He has delivered operational excellence through governance reform and cost restructuring and led turnarounds with disciplined capital allocation. Additionally, he has driven growth through IP monetisation, international expansion, and global strategic partnerships.

Mr Vesali commented: "I am excited about the opportunity ahead for Wellnex and see it as my responsibility to further enhance confidence with our shareholders. There is a clear pathway to further refine our strategy and deliver value and I look forward to working with the Board to assist Wellnex in delivering on its full potential."

The Board's immediate focus will be to continue leveraging the two core pillars of the Company's strategy:

1.   Driving continued growth of Wellnex's category-leading consumer brand Pain Away which holds Australia's number one position in natural topical pain relief with an estimated 14% market share.

2.   Continued expansion of our contract manufacturing partnerships in the softgel analgesics market where the Company already holds supply agreements with leading pharmaceutical brands such as UK giant Haleon.

A further announcement containing the requisite information under paragraph (g) of Schedule Two of the AIM Rules regarding Mr Vesali will be made following completion of Nominated Adviser due diligence and his appointment to the Board.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)                                  Reach Markets

Zack Bozinovski                                                               T: 1300 805 795

Chief Executive Officer & Managing Director                   E: [email protected]

P: +61 3 8399 9419

E: [email protected]

UK Investors

Strand Hanson (Financial & Nominated Advisor)     

James Harris / Richard Johnson                                       Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)                                 [email protected]

Sebastian Wykeham     

S.P. Angel Corporate Finance LLP (Joint Broker)            Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

To learn more, please visit: www.Wellnex Lifelife.com.au/